董事会谨此知会股东及有意投资人士，于截至2025年6月30日止报告期结束后发生一项非调整事项。于 2025年7月24日，公司可换股债券持有人悉数行使其换股权。因此，117,647,058股换股股份已于2025年7 月25日配发及发行予可换股债券持有人。该可换股债券转换后，在集团截至2025年12月31日止年度的年 度业绩中确认非现金会计调整，归因于对相关会计准则的应用及遵守而反映的额外亏损约4.765亿港 元。 格隆汇8月8日丨百仕达控股(01168.HK)发布公告，集团预期截至2025年6月30日止六个月录得公司拥有 人应占亏损不超过5.35亿港元，而去年同期则录得约1.505亿港元。有关亏损增加乃主要由于截至2025年 6月30日止六个月确认公司可换股债券的公允值亏损约4.979亿港元。 ...

期间有关亏损增加乃主要归因于来自向中国西南的页岩气田提供增产服务的收益大幅减少，乃由于一名 主要客户根据其内部开采计划，将若干页岩气田的增产工程延迟到2025年下半年。此外，在中东市场的 监督服务合约已于2024年上半年届满，亦导致集团的收益减少，乃由于报告期间概无收入产生自服务合 约。 格隆汇8月8日丨百勤油服(02178.HK)发布公告，集团预计截至2025年6月30日止六个月将录得公司拥有 人应占亏损不多于15.0百万港元，而2024年上半年公司拥有人应占亏损则为约0.4百万港元，较2024年上 半年亏损增加不多于14.6百万港元。 ...

智通财经APP讯，新达控股(08471)发布公告，郝冰清先生获委任为非执行董事，自2025年8月8日起生 效。 ...

车载镜头出货量同比上升28.8%，主要是因为客户端的需求有所提升。 手机镜头出货量同比下降14.6%，主要是因为公司专注于中高端案子，且产品结构较去年同期显著改 善。 舜宇光学科技(02382)发布公告，于2025年7月，手机镜头出货量为约9856.5万件，环比增加3.7%，同比 减少14.6%;车载镜头出货量为1134.9万件，环比增加2.7%，同比增加28.8%。手机摄像模组出货量为 4262.9万件，环比增加1.7%，同比减少2.9%。 ...

味千(中国)(00538)发布公告，与截至2024年6月30日止6个月本公司拥有人应占亏损约人民币720万元相 比，预期本集团截至2025年6月30日止6个月将扭亏为盈，取得本公司拥有人应占溢利约人民币1000万元 至4000万元。 董事会预期本集团于该期间将由亏转盈，主要受惠于门店数量较去年同期增加，带动收入增长。此外， 本集团积极优化营运流程及调整办公室人力架构，以提升运营效率并控制成本。这些因素共同促使经营 溢利较去年同期有所增长。 ...

Core Viewpoint - China Biotechnology Services (08037) expects a significant reduction in losses for the first half of 2025, projecting a loss attributable to shareholders of no more than HKD 33 million, which is approximately 59% lower than the loss of HKD 79.917 million in the same period of 2024 [1] Group 1 - The improvement in operational performance is primarily attributed to successful cost control measures implemented by the company [1] - The company has experienced an increase in gross margin and a reduction in administrative expenses [1] - The company received compensation income of approximately HKD 14 million from insurance claims related to damages caused by heavy rainfall to construction sites in Hainan during 2024 [1]

力图控股(01008)发布公告，集团预期于截至2025年6月30日止6个月取得公司拥有人应占溢利约100万港 元至500万港元，而2024年同期则取得公司拥有人应占溢利约2880万港元。公司拥有人应占溢利减少主 要由于截至2025年6月30日止6个月就分类为持作出售的资产减值亏损计提拨备约2990万港元(2024年： 无)。 ...

香港联交所最新资料显示，8月8日，叶永春减持立高控股(08472)450万股，每股作价0.405港元，总金额 为182.25万港元。减持后最新持股数目为561.45万股，最新持股比例为4.87%。 ...

大唐西市(00620)发布公告，林晓凌已获委任为执行董事;及戴智杰已获委任为独立非执行董事，自2025 年8月8日起生效。 戴智杰已获委任为董事会审核委员会及薪酬委员会成员;及蔡宏图已获调任为薪酬委员会主席，自2025 年8月8日起生效。 ...

Group 1 - BlackRock invested over $1.2 billion in ETH, significantly outpacing its $267 million investment in BTC, indicating a shift in Wall Street's capital direction from Bitcoin as "digital gold" to Ethereum as "digital oil" [1] - The rapid growth of BlackRock's Ethereum ETF (ETHA) from $5 billion to over $10 billion in just 10 days reflects changing investor sentiment towards Ethereum [1] Group 2 - Huajian Medical announced its transformation into the first enhanced Ethereum treasury company in Hong Kong, marking a strategic advancement in the market [2] - The company initiated a global enhanced Ethereum treasury strategy with a multi-layered "downside protection" mechanism and active "yield enhancement" strategies [3] Group 3 - Huajian Medical partnered with HashKey Group to establish a compliant trading channel for large-scale ETH transactions and to explore the integration of crypto assets with real-world assets (RWA) [6] - The company approved the purchase of 5,190 ETH at an average price of HKD 28,798.21, totaling HKD 149 million, as a significant step in its treasury strategy [7] Group 4 - Wall Street's consensus indicates that Ethereum is becoming a necessary asset for institutional investment, supported by five core value pillars including its deflationary nature and yield generation capabilities [8][9] - Ethereum's role as a foundational settlement asset in the DeFi ecosystem positions it as a preferred choice for RWA tokenization and stablecoin issuance [9] Group 5 - Huajian Medical's Ethereum treasury strategy is closely linked to its core business of medical RWA tokenization, aiming to create a unique ecosystem for innovative drug assets [10] - The company's ivd.xyz exchange is designed to facilitate the issuance and trading of medical RWA, integrating Ethereum as a core asset for governance and liquidity [10] Group 6 - The treasury strategy includes an "insurance mechanism" to mitigate volatility risks and a systematic investment approach to smooth costs [13][14] - Huajian Medical aims to address the challenges in innovative drug development financing through its tokenization strategy, enhancing investment efficiency [15] Group 7 - The market is recognizing the potential for Huajian Medical's treasury model to achieve significant valuation, drawing parallels to MicroStrategy's success with Bitcoin [17] - The company's stock price surged by 118% in July and 38.43% on August 6, indicating strong market interest and potential for value discovery [19] Group 8 - Huajian Medical's strategic vision includes applying for stablecoin licenses in both Hong Kong and the U.S., aiming to connect innovative drug assets with global capital through the Ethereum ecosystem [24] - The company's ambition is to leverage Ethereum's properties to create a new benchmark in the Hong Kong market, facilitating the global circulation of Chinese biomedical assets [24]